Eugene Hutchinson is an associate in White & Case's New York office and a member of the Firm's Global Competition and Antitrust Group. His practice focuses on complex antitrust matters and counselling, with a specific focus on class action litigation at the cutting edge of pharmaceutical antitrust and intellectual property, including "reverse payment" and "product hopping" pharmaceutical litigation. Eugene has extensive experience in all phases of litigation, including discovery management, summary judgment motions and oppositions to motions for class certification, working with experts on liability and class certification issues, and trial.
Eugene also maintains an active pro bono practice, including the successful representation of a wrongfully convicted man at trial in a federal civil rights action to secure a verdict awarding compensation for 27 years of wrongful imprisonment.
Eugene graduated from Hofstra University School of Law magna cum laude in 2016, where he served as an Articles Editor on the Hofstra Law Review.
Drug Pricing Issues to Watch in 2022 (2022)
HHS Report Reiterates Biden Administration Support for Wide-Ranging Action to Address Drug Prices (2021)
Elimination of Medicaid Rebate Cap in the Latest COVID-19 Relief Package—The First Legislative Action on Drug Pricing Under the Biden Administration (2021)
Supreme Court Green Lights Arkansas Law Regulating PBM Pricing Practices (2020)
Impact of the CARES Act on the Medical Device Industry (2020)
Impact of the CARES Act on the Pharmaceutical and Medical Devices Industries (2020)